Faeth Therapeutics, Inc. (NasdaqCM: FTH)
Health Care · Biotechnology · US
$32.00
-1.05% today · +302.0% 1Y
Faeth Therapeutics, Inc. (NasdaqCM: FTH) operates in the Biotechnology industry within the Health Care sector. The company is valued at $826.89M and employs 29 people.
Over the last twelve months the share price has gained 302.0%, trading between 7.45 and 37.90.
Tweenvest scores Faeth Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
FTH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $826.89M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -82.46
- Dividend yield
- —
- Beta (5Y)
- -0.31
- 52-week high
- $37.90
- 52-week low
- $7.45
- Avg volume (3M)
- —
- Shares outstanding
- 25.84M
- Employees
- 29
- Next earnings
- —
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
- Founded
- 1999
- Listed since
- Feb 4, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.